# Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer

> **NCT06763029** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 36 (estimated)

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** Irinotecan liposomes combined with cetuximab + vermofenib

## Key facts

- **NCT ID:** NCT06763029
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-26
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06763029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06763029, "Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06763029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*